Matches in SemOpenAlex for { <https://semopenalex.org/work/W2405118428> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2405118428 endingPage "56" @default.
- W2405118428 startingPage "146" @default.
- W2405118428 abstract "The aim of this study was to compare the efficacy of lamivudine therapy between chronic hepatitis B (CHB) patients, whose ALT levels less than 2 times the upper limit of normal (ULN) and patients whose ALT levels are more than 2 times ULN.We retrospectively analyzed 508 consecutive patients with HBeAg-positive CHB who were treated with lamivudine for 1 year or more. Forty-six patients (Group A) with pretreatment ALT levels less than 2 times ULN were retrospectively compared with 462 patients (Group B) whose ALT levels are more than 2 times ULN.HBeAg seroconversion was achieved in 15 (32.6%) of group A and 162 (35.1%) of group B. The cumulative rates of HBeAg seroconversion in group A and B were 19% and 21% at 12 months; 35% and 31% at 24 months; and 38% and 39% at 36 months, respectively. HBV breakthrough was observed in 20 (43.5%) of group A and 192 (41.6%) of group B. The cumulative breakthrough rates of group A and B were 18% and 12% at 12 months; 33% and 29 % at 18 months; 45% and 42% at 24 months, respectively. Post-treatment relapse in group A and B occurred in 56% (5/9) and 41% (44/108), respectively. Therefore, the rates of the HBeAg seroconversion, breakthrough, and post-treatment relapse were not significantly different between these two groups.Lamivudine therapy in HBeAg-positive CHB patients whose ALT levels are minimally elevated is as effective as in treatment of the patients whose pretreated ALT levels are twice more than ULN." @default.
- W2405118428 created "2016-06-24" @default.
- W2405118428 creator A5001822288 @default.
- W2405118428 creator A5007735500 @default.
- W2405118428 creator A5015683446 @default.
- W2405118428 creator A5015924856 @default.
- W2405118428 creator A5039396082 @default.
- W2405118428 creator A5045633517 @default.
- W2405118428 creator A5056964894 @default.
- W2405118428 creator A5058708579 @default.
- W2405118428 creator A5075088268 @default.
- W2405118428 date "2007-06-01" @default.
- W2405118428 modified "2023-09-23" @default.
- W2405118428 title "[Clinical outcomes of lamivudine therapy in HBeAg positive chronic hepatitis B with minimally elevated ALT]." @default.
- W2405118428 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17585188" @default.
- W2405118428 hasPublicationYear "2007" @default.
- W2405118428 type Work @default.
- W2405118428 sameAs 2405118428 @default.
- W2405118428 citedByCount "0" @default.
- W2405118428 crossrefType "journal-article" @default.
- W2405118428 hasAuthorship W2405118428A5001822288 @default.
- W2405118428 hasAuthorship W2405118428A5007735500 @default.
- W2405118428 hasAuthorship W2405118428A5015683446 @default.
- W2405118428 hasAuthorship W2405118428A5015924856 @default.
- W2405118428 hasAuthorship W2405118428A5039396082 @default.
- W2405118428 hasAuthorship W2405118428A5045633517 @default.
- W2405118428 hasAuthorship W2405118428A5056964894 @default.
- W2405118428 hasAuthorship W2405118428A5058708579 @default.
- W2405118428 hasAuthorship W2405118428A5075088268 @default.
- W2405118428 hasConcept C126322002 @default.
- W2405118428 hasConcept C141071460 @default.
- W2405118428 hasConcept C159654299 @default.
- W2405118428 hasConcept C203014093 @default.
- W2405118428 hasConcept C2522874641 @default.
- W2405118428 hasConcept C2775940106 @default.
- W2405118428 hasConcept C2777382497 @default.
- W2405118428 hasConcept C2777410769 @default.
- W2405118428 hasConcept C2777451964 @default.
- W2405118428 hasConcept C2777785397 @default.
- W2405118428 hasConcept C2777869810 @default.
- W2405118428 hasConcept C2780593183 @default.
- W2405118428 hasConcept C2780678043 @default.
- W2405118428 hasConcept C3020491458 @default.
- W2405118428 hasConcept C71924100 @default.
- W2405118428 hasConcept C90924648 @default.
- W2405118428 hasConceptScore W2405118428C126322002 @default.
- W2405118428 hasConceptScore W2405118428C141071460 @default.
- W2405118428 hasConceptScore W2405118428C159654299 @default.
- W2405118428 hasConceptScore W2405118428C203014093 @default.
- W2405118428 hasConceptScore W2405118428C2522874641 @default.
- W2405118428 hasConceptScore W2405118428C2775940106 @default.
- W2405118428 hasConceptScore W2405118428C2777382497 @default.
- W2405118428 hasConceptScore W2405118428C2777410769 @default.
- W2405118428 hasConceptScore W2405118428C2777451964 @default.
- W2405118428 hasConceptScore W2405118428C2777785397 @default.
- W2405118428 hasConceptScore W2405118428C2777869810 @default.
- W2405118428 hasConceptScore W2405118428C2780593183 @default.
- W2405118428 hasConceptScore W2405118428C2780678043 @default.
- W2405118428 hasConceptScore W2405118428C3020491458 @default.
- W2405118428 hasConceptScore W2405118428C71924100 @default.
- W2405118428 hasConceptScore W2405118428C90924648 @default.
- W2405118428 hasIssue "2" @default.
- W2405118428 hasLocation W24051184281 @default.
- W2405118428 hasOpenAccess W2405118428 @default.
- W2405118428 hasPrimaryLocation W24051184281 @default.
- W2405118428 hasRelatedWork W2349642934 @default.
- W2405118428 hasRelatedWork W2362861782 @default.
- W2405118428 hasRelatedWork W2363870059 @default.
- W2405118428 hasRelatedWork W2366294606 @default.
- W2405118428 hasRelatedWork W2375358607 @default.
- W2405118428 hasRelatedWork W2375807400 @default.
- W2405118428 hasRelatedWork W2378243949 @default.
- W2405118428 hasRelatedWork W2380696823 @default.
- W2405118428 hasRelatedWork W2405118428 @default.
- W2405118428 hasRelatedWork W3030313012 @default.
- W2405118428 hasVolume "13" @default.
- W2405118428 isParatext "false" @default.
- W2405118428 isRetracted "false" @default.
- W2405118428 magId "2405118428" @default.
- W2405118428 workType "article" @default.